Open AccessA patient with atrial fibrillation and diabetes: selecting the optimal anticoagulant therapy regimen
Author(s) -
А. Г. Обрезан,
Alexander É. Filippov,
A.A. Obrezan
Publication year - 2021
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2021-4508
Subject(s) - medicine , atrial fibrillation , diabetes mellitus , stroke (engine) , cardiology , heart failure , type 2 diabetes , coronary artery disease , concomitant , regimen , anticoagulant therapy , anticoagulant , mechanical engineering , engineering , endocrinology
Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, hypertension, heart failure, while strokes in patients with AF and diabetes are more severe. Diabetes, in turn, causes the angiopathies and cardiopathy. There is a higher risk of both thrombotic and bleeding events in patients with AF and T2D. The article discusses the mutual burden of T2D and AF, as well as the risk scores for thrombotic, thromboembolic, and bleeding events. Anticoagulant therapy takes a special place in improving the prognosis in AF patients. Numerous studies and actual clinical practice have demonstrated the effectiveness of anticoagulants in the prevention of stroke and other comorbidities.